US Broker Ratings

Addus HomeCare Corporation (ADUS) Stock Analysis: Unpacking a Potential 16.43% Upside in the Healthcare Sector

Addus HomeCare Corporation (NASDAQ: ADUS), a leading provider of personal care services across the United States, offers a compelling investment opportunity in the healthcare sector. With..

Scholar Rock Holding Corporation (SRRK) Stock Analysis: A Promising 75% Upside in the Biotechnology Sector

Scholar Rock Holding Corporation (NASDAQ: SRRK) is capturing the attention of investors within the healthcare sector, thanks to its innovative approach in the biotechnology industry and..

HUTCHMED (China) Limited (HCM): Investor Outlook with 45% Potential Upside

HUTCHMED (China) Limited (NASDAQ: HCM), a prominent player in the healthcare sector, is drawing attention with a significant potential upside of 45.21% based on its current..

Enovis Corporation (ENOV): Unpacking the 81.60% Potential Upside and Analyst Consensus

Enovis Corporation (NYSE: ENOV), a key player in the healthcare sector specializing in medical devices, is capturing investor attention with its substantial 81.60% potential upside. This..

Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: High Revenue Growth and Strong Buy Ratings Signal Promising Upside

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is making waves in the biotechnology sector, with its innovative therapies for a range of complex conditions. With a market capitalization..

Xenon Pharmaceuticals Inc. (XENE) Stock Analysis: Exploring a 106% Upside Potential Amid Strong Buy Ratings

Xenon Pharmaceuticals Inc. (XENE), a Canadian biotechnology company, is making waves in the healthcare sector with its promising pipeline of neuroscience-focused therapeutics. With a market cap..

Organon & Co. (OGN) Stock Analysis: Evaluating the 24% Return on Equity in a Challenging Healthcare Landscape

Organon & Co. (NYSE: OGN), a stalwart in the healthcare sector specializing in women’s health solutions and biosimilars, offers a compelling yet complex investment narrative. With..

Alvotech (ALVO) Investor Outlook: Analyzing the 43% Potential Upside in the Biosimilar Market

Alvotech (NASDAQ: ALVO) stands at the forefront of the biosimilar medicine market, offering a diverse range of products targeting a spectrum of conditions from autoimmune disorders..

ACADIA Pharmaceuticals Inc. (ACAD): Investor Outlook Reveals 54% Potential Upside Amid Robust Pipeline

For investors seeking opportunities in the biotechnology sector, ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) presents an intriguing prospect with a notable potential upside of 54.17% based on..

Sotera Health Company (SHC) Stock Analysis: Exploring a 28% Potential Upside for Investors

Sotera Health Company (NASDAQ: SHC) stands out in the healthcare sector with its pivotal role in providing sterilization solutions, lab testing, and advisory services. Operating through..

Lantheus Holdings, Inc. (LNTH): Investor Outlook Reveals 7.31% Potential Upside in Healthcare Diagnostics

Lantheus Holdings, Inc. (LNTH) stands at the forefront of the healthcare diagnostics industry, developing and commercializing a diverse array of products that aid clinicians in diagnosing..

Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Navigating a 26.53% Potential Upside Amidst Biotechnology Challenges

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a prominent player in the biotechnology sector, offers a compelling opportunity for investors seeking exposure to the healthcare industry. With a..

Alkermes plc (ALKS) Stock Analysis: A Strong Buy with a 36% Upside Potential

Alkermes plc (NASDAQ: ALKS) is capturing the attention of investors by showing significant promise in the healthcare sector. With a market capitalization of $6.92 billion, Alkermes..

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech with 67% Upside Potential

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is making waves in the biotechnology sector with its focus on rare neuroendocrine diseases. Headquartered in Boston, Massachusetts, this commercial-stage biopharmaceutical..

Cytokinetics, Incorporated (CYTK) Stock Analysis: Biotech Innovator Poised for 76.59% Upside

Cytokinetics, Incorporated (NASDAQ: CYTK) is capturing the attention of investors with its substantial projected upside of 76.59%, according to recent analyst ratings. Operating in the biotechnology..

Merit Medical Systems, Inc. (MMSI) Stock Analysis: Exploring a 13.94% Potential Upside for Investors

Merit Medical Systems, Inc. (NASDAQ: MMSI), a prominent player in the healthcare sector, offers investors a compelling opportunity as it navigates the rapidly evolving landscape of..

Legend Biotech Corporation (LEGN) Stock Analysis: A 146.87% Potential Upside in the Biotech Sector

Legend Biotech Corporation (NASDAQ: LEGN), a prominent player in the biotechnology sector, offers an intriguing proposition for investors eyeing the healthcare industry. With a market capitalization..

TransMedics Group, Inc. (TMDX) Stock Analysis: Unlocking a 39% Upside Potential in Healthcare Innovation

Investors in the healthcare sector are no strangers to the allure of breakthrough technologies, and TransMedics Group, Inc. (NASDAQ: TMDX) stands out as a beacon of..

Bausch + Lomb Corporation (BLCO) Stock Analysis: Navigating a 17.6% Upside Potential in Eye Health Innovation

Bausch + Lomb Corporation (NYSE: BLCO), a stalwart in the healthcare sector, particularly in the medical instruments and supplies industry, is charting an intriguing course for..

Waystar Holding Corp. (WAY)

⚠️ No article content returned.

..
Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds